期刊
EPIGENOMICS
卷 10, 期 8, 页码 1085-1101出版社
FUTURE MEDICINE LTD
DOI: 10.2217/epi-2017-0171
关键词
cancer epigenetics; DNA methylation; DNA methyltransferase
资金
- Medical Research Council [MR/J007773/1]
- MRC [MR/J007773/1] Funding Source: UKRI
Aim: 5-aza-2' deoxycytidine (Aza) is used to treat myelodysplastic syndrome and is in trials for other cancers. It acts chiefly as a hypomethylating agent inhibiting DNMT1. A lack of understanding of off-target effects in normal cells hinders wider usage. Materials & methods: We compared treatment of the same normosomic, nontransformed fibroblast cell line with Aza and SMARTpool siRNA against DNMT1. Methylation and transcription were assayed using Illumina 450k and HT12 arrays. Results: Both Aza and DNMT1 siRNA caused overall hypomethylation, with siRNA more efficient at demethylating gene bodies. Hypomethylation at the promoters of many histones, and hypermethylation at multiple sites genome wide, were unique to Aza treatment. Conclusion: Aza had important unique effects and targets compared with DNMT1 inhibition via siRNA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据